Protective effects of estradiol on TRAIL-induced apoptosis in a human oligodendrocytic cell line: Evidence for multiple sites of interactions

Cell Death and Differentiation

Volumn 11, Issue 5, 2004, Pages 503-511

  Cantarella, G ^a   Risuglia, N ^a   Lombardo, G ^a   Lempereur, L ^a   Nicoletti, F ^a   Memo, M ^b   Bernardini, R ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Demyelinating disease; Estradiol; Oligodendroglia; Proapoptotic cytokines; Protection

Indexed keywords

CASPASE 3; CASPASE 8; DEATH RECEPTOR 5; ESTRADIOL; FAS ASSOCIATED DEATH DOMAIN PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN BCL XL; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CELL LINE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NORTHERN BLOTTING; OLIGODENDROGLIA; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARABIDOPSIS PROTEINS; CASPASES; CELLS, CULTURED; ENZYME INHIBITORS; ESTRADIOL; FATTY ACID DESATURASES; HELA CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MEMBRANE GLYCOPROTEINS; OLIGODENDROGLIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442702973     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401367     Document Type: Article

References (54)

1. Colman D, Lubetzki C and Reingold S (2003) Multiple paths towards repair in multiple sclerosis. Trends Neurosci. 26: 59-61
2. Carson MJ (2002) Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. Glia 40: 218-231
3. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Bruck W, Lucchinetti C, Schmidbauer M, Jellinger K and Lassmann H (2003) Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J. Neuropathol. Exp. Neurol. 62: 25-33
4. Cimini A, Bernardo A, Cifone MG, Di Marzio L, Di Loreto S, Cifone G and Di Muzio L (2003) TNFalpha downregulates PPARdelta expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. Glia 41: 3-14
5. Robertson J, Beaulieu JM, Doroudchi MM, Durham HD, Julien JP and Mushynski WE (2001) Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha. J. Cell Biol. 155: 217-226
6. Satoh JI and Kuroda Y (2001) Alpha-synuclein expression is up-regulated in NTera2 cells during neuronal differentiation but unaffected by exposure to cytokines and neurotrophic factors. Parkinsonism Relat. Disord. 8: 7-17
7. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U and Zipp F (2000) Human brain-cell death induced by tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356: 827-828
8. Wosik K, Antel J, Kuhlmann T, Bruck W, Massie B and Nalbantoglu G (2003) Oligodendrocyte injury in multiple sclerosis: a role for p53. J. Neurochem. 85: 635-644
9. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM (1997a) The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113
10. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin R and Rauch CT (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16: 5386-5397
11. Pan G, Ni J, Wei Y, Yu G, Gentz R and Dixit VM (1997b) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818
12. Sheridan JP, Marsters S, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821
13. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA and Goodwin RG (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7: 813-820
14. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sanders S, Van G, Tarpley J, Derby P, Lee R and Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319
15. Shipman CM and Croucher PI (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63: 912-916
16. Dorr J, Bechmann I, Waiczies S, Aktas O, Walczak H, Krammer PH, Nitsch R and Zipp F (2002) Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain. J. Neurosci. 22: RC209
17. Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel J, Schenkel J, Herdegen T and Debatin KM (1999) CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19: 3809-3817
18. Cantarella G, Uberti D, Carsana T, Lombardo G, Bernardini R and Memo M (2003) Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity. Cell Death. Differ. 10: 134-141
19. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N and Tschopp J (1997) TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NK-κB. Immunity 7: 831-836
20. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S and Liu ZG (2000) The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol. Cell. Biol. 20: 6638-6645
21. Duquette P and Girard M (1993) Hormonal factors in susceptibility to multiple sclerosis. Curr. Opin. Neurol. Neurosurg. 6: 195-201
22. Santagati S, Melcangi RC, Celotti F, Martini L and Maggi A (1994) Estrogen receptor is expressed in different types of glial cells in culture. J. Neurochem. 63: 2058-2064
23. Confabreux C, Hutchinson M, Hourse MM, Cortinovis-Tourniaire P and Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. N. Engl. J. Med. 339: 285-291
24. Bebo Jr BF, Schuster JC, Vandenbark AA and Offner H (1999) Androgens alter the cytokine profile and reduce encephalitogenicity of myelin reactive T cells. J. Immunol. 162: 35-40
25. Voskuhl RR, Pitchekian-Halabi H, MacKenzie-Graham A, McFarland HF and Raine CS (1996) Gender differences in autoimmune demyelination in the mouse: implications for multiple sclerosis. Ann. Neurol. 39: 724-733
26. Zhang Y, Tounekti O, Akerman B, Goodyer CG and LeBlanc A (2001) 17-β-estradiol induces an inhibitor of active caspases. J. Neurosci. 21: 1-6
27. Lee MW, Park SC, Yang YG, Yim SO, Chae HS, Bach JH, Lee HJ, Kim KY, Lee WB and Kim SS (2002) The involvement of reactive oxygen species (ROS) and p38 mitogen-activated protein (MAP) kinase in TRAIL/Apo2L-induced apoptosis. FEBS Lett. 512: 313-318
28. Matysiak M, Jurewicz A, Jaskolski D and Selmaj K (2002) TRAIL induces death of human oligodendrocytes isolated from adult brain. Brain 125: 2469-2480
29. McLaurin J, Trudel GC, Shaw IT, Antel JP and Cashman NR (1995) A human glial hybrid cell line differentially expressing genes subserving oligodendrocyte and astrocyte phenotype. J. Neurobiol. 26: 283-293
30. Haczynski J, Tarkowski R, Jarzabek K, Slomczynska M, Wolczynski S, Magoffin DA, Jakowicki JA and Jakimiuk AJ (2002) Human cultured skin fibroblasts express estrogen receptor alpha and beta. Int. J. Mol. Med. 10: 149-153
31. Green PS and Simpkins JW (2000) Neuroprotective effects of estrogens: potential mechanisms of action. Int. J. Dev. Neurosci. 18: 347-358
32. Lee SJ and McEwen BS (2001) Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 41: 569-591
33. Smolnikar K, Loffek S, Schulz T, Michna H and Diel P (2000) Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Breast Cancer Res. Treat. 63: 249-259
34. Sunyer T, Lewis J, Collin-Osdoby P and Osdoby P (1999) Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J. Clin. Invest. 103: 1409-1418
35. Deb S, Tessier C, Prigent-Tessier A, Barkai U, Ferguson-Gottschall S, Srivastava RK, Faliszek J and Gibori G (1999) The expression of interleukin-6 (IL-6), IL-6 receptor, and gp130-kilodalton glycoprotein in the rat decidua and a decidual cell line: regulation by 17beta-estradiol and prolactin. Endocrinology 140: 4442-4450
36. LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ and Pribluda VS (2003) 2-methoxyestradiol upregulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. 63: 468-475
37. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH and Walczak H (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609
38. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620
39. Pawlowski JE, Nesterov A, Scheinman RI, Johnson TR and Kraft AS (2000) NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptoss-inducing ligand (TRAIL). Anticancer Res. 20: 4243-4255
40. Kim H, Bang OY, Jung MW, Ha SD, Hong HS, Huh K, Kim SU and Mook-Jung I (2000) Neuroprotective effects of estrogen against beta-amyloid toxicity are mediated by estrogen receptors in cultured neuronal cells. Neurosci. Lett. 302: 58-62
41. Kauser K, Sonnenberg D, Diel P and Rubanyi GM (1998) Effect of 17beta-oestradiol on cytokine-induced nitric oxide production in rat isolated aorta. Br. J. Pharmacol. 123: 1089-1096
42. Sawada H, Ibi M, Kihara T, Urushitani M, Honda K, Nakanishi M, Akaike A and Shimohama S (2000) Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J. 14: 1202-1214
43. Wise PM, Dubal DB, Wilson ME and Rau SW (2000) Estradiol is a neuroprotective factor in in vivo and in vitro models of brain injury. J. Neurocytol. 29: 401-410
44. Dhandapani KM and Brann DW (2002) Estrogen-astrocyte interactions: implications for neuroprotection. BMC Neurosci. 3: 6
45. Garcia-Segura LM, Naftolin F, Hutchison JB, Azcoitia I and Chowen JA (1999) Role of astroglia in estrogen regulation of synaptic plasticity and brain repair. J. Neurobiol. 40: 574-584
46. Burger D and Dayer JM (2002) Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-alpha production in contact-mediated activation of monocytes by T lymphocytes. Ann. N Y Acad. Sci. 966: 464-473
47. Cimini A, Bernardo A, Cifone MG, Di Marzio L, Di Loreto S, Cifone G and Di Muzio L (2003) TNFalpha downregulates PPARdelta expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. Glia 41: 3-14
48. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M and Rodriguez M (2002) Activity of a newly identified serine protease in CNS demyelination. Brain 125: 1283-1296
49. Liu HY, Buenafe AC, Matejuk A, Ito A, Zamora A, Dwyer J, Vandenbark AA and Offner H (2002) Estrogen inhibition of EAE involves effects on dendritic cell function. J. Neurosci. Res. 70: 238-248
50. Matejuk A, Dwyer J, Zamora A, Vandenbark AA and Offner H (2002) Evaluation of the effects of 17beta-estradiol (17beta-e2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray. Endocrinology 143: 313-319
51. Craighead MW, Tiwari P, Keynes RG and Waters CM (1999) Human oligodendroglial cell line, MO3.13, can be protected from apoptosis using the general caspase inhibitor zVAD-FMK. J. Neurosci. Res. 57: 236-243
52. Darzynkiewicz Z, Li X and Gong J (1994) Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol. 41: 15-38
53. Jones KH and Kniss DA (1987) Propidium iodide as a nuclear counterstain for immunofluorescence studies on cells in culture. J. Histochem. Cytochem. 35: 123-125
54. Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159